Pacific Biosciences of California, Inc. (PACB) P/E Ratio History
Deep ValueTrading at -0.8x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2020–2020
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Pacific Biosciences of California, Inc. (PACB) trades at a price-to-earnings ratio of -0.8x, with a stock price of $1.40 and trailing twelve-month earnings per share of $-0.42.
The current P/E is 100% below its 5-year average of 288.2x. Over the past five years, PACB's P/E has ranged from a low of 288.2x to a high of 288.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, PACB trades at a 103% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, PACB trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PACB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PACB Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PACB P/E vs Peers
Device suppliers, distribution, and services peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $25B | 29.7 | 7.02 | +171%Best | |
| $173B | 26.2 | 12.40 | +7% | |
| $125B | 35.2 | - | -5% | |
| $36B | 27.8 | 1.89Best | +3% | |
| $8B | 10.1Lowest | - | +143% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PACB Historical P/E Data (2020–2020)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2020 Q4 | - | $25.94 | $0.09 | 288.2x | +0% |
Average P/E for displayed period: 288.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PACB — Frequently Asked Questions
Quick answers to the most common questions about buying PACB stock.
What is PACB's P/E ratio?
Pacific Biosciences of California, Inc. (PACB) trailing twelve-month P/E ratio is -0.8x, based on TTM diluted EPS of $-0.42. The 5-year average P/E is 288.2x and the historical range spans 288.2x to 288.2x.
Is PACB stock overvalued or undervalued?
PACB trades at -0.8x P/E, below its 5-year average of 288.2x. At the 0th percentile of its historical range (288.2x–288.2x), the stock is priced at a discount to its own history.
Is PACB stock expensive?
No, PACB is not expensive on a historical basis. The current P/E of -0.8x is below the 5-year average of 288.2x and sits at the 0th percentile of its valuation range.
What is PACB's historical P/E range?
Over the past 5 years, PACB's P/E ratio has ranged from 288.2x to 288.2x, with a median of 288.2x and an average of 288.2x. The current P/E of -0.8x places the stock at the 0th percentile of this range. Full historical data spans 2020–2020.
How does PACB's P/E compare to the S&P 500?
PACB trades at -0.8x P/E versus the S&P 500 median of 24.4x. The 103% discount to the market suggests lower growth expectations or perceived higher risk.
How does PACB's valuation compare to Healthcare peers?
Pacific Biosciences of California, Inc. P/E of -0.8x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PACB's PEG ratio?
PACB PEG ratio is N/A, based on a P/E of -0.8x and EPS growth of -70.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is PACB's earnings yield?
PACB earnings yield is N/A, the inverse of its -0.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.